Senores Pharma Seeks Shareholder Nod for IPO Fund Use Variation

Senores Pharmaceuticals Limited announced an outcome of its Board Meeting held on June 29, 2026. The Board, on the recommendation of the Audit Committee, has approved a variation in the utilization of unutilized IPO proceeds. The company plans to reallocate ₹1000.16 million from the total IPO proceeds of ₹5000.00 million. This proposed variation is subject to the approval of the shareholders through a postal ballot. The board meeting commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M. (IST). The company will also host this information on its website.